Special Issue "Multikinase Inhibitors and Cancer"
Deadline for manuscript submissions: 30 November 2020.
Interests: cancer; cell biology; gravitational biology; space medicine; tissue engineering; pharmacology; apoptosis; SOX transcription factors
Special Issues and Collections in MDPI journals
Special Issue in International Journal of Molecular Sciences: Cell and Molecular Biology of Thyroid Disorders
Special Issue in International Journal of Molecular Sciences: Cell and Molecular Biology of Thyroid Disorders 2.0
Special Issue in International Journal of Molecular Sciences: Microgravity and Space Medicine
Cancer is a burden of humankind with high morbidity and mortality. It is the second leading cause of death worldwide and is responsible for an estimated 18.1 million (95% UI: 17.5-18.7 million) new cases of cancer (17 million excluding non-melanoma skin cancer) and 9.6 million (95% UI: 9.3-9.8 million) deaths from cancer (9.5 million excluding non-melanoma skin cancer) worldwide in 2018 (WHO Global Cancer Observatory (GLOBOCAN) 2018).
Tumor formation and progression is a multifactorial process. It involves the dysregulation of cell growth and proliferation, as well as angiogenesis (the formation of new blood vessels), which depend on numerous different signaling pathways each, including kinases as a milestone of function.
In recent times, anticancer therapies by means of multikinase inhibitors (MKI) targeting several kinases have proven promising. MKI inhibit a number of intracellular and cell surface kinases, decreasing tumor growth and replication of different types of cancers. Hence, they have become a new therapeutic option in various cancer types. Over the last few years, new MKI have been developed. These substances appear useful for targeted systemic therapy and have been approved after their efficacy was demonstrated in clinical trials. Currently, MKI are, for example, used in patients with radioiodine (RAI)-refractory advanced metastatic thyroid cancer, and trials have shown clinical benefits for MKI treatment in patients with advanced renal cell cancer, progressive medullary thyroid cancer, breast cancer, gastrointestinal tumors, and others.
However, there are also reports about a broad range of moderate to severe adverse effects associated with treatment. Adverse effects like hypertension may endanger a future successful application of MKI for treating advanced cancers in clinical practice.
This Special Issue shall cover results of studies using animal or cell culture models to investigate the effects of MKI on cancer, applying molecular biological methods. This issue will also publish reports on patients, providing novel mechanistic insights into new aspects that may impact clinical therapy with MKI. In addition, reviews about the current status of new therapy options in different cancer types or about the adverse effects associated with MKI treatment will be published.
Prof. Dr. Daniela Grimm
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- multikinase inhibitors
- animal model
- cell culture
- OMICS investigation
- signal transduction
- clinical trials
- adverse effects